In 1991, Kiely J.S. used it to screen enzyme inhibitors, and, later, the literature reported that pancreatic lipase inhibitors in the middle have a preeminent behavior on the treatment of obesity and prevention of its complications [8,9,10]. The gene discussed is PNLIP; the disease is obesity due to melanocortin 4 receptor deficiency.